In addition, in the study, we also showed the inversed
correlation between EGFR mutation and methylation BRCA1 and
MGMT (Table 3.15). The study of methylation of BRCA1 and MGMT
has received limited attention in lung cancer. However, our results
showed that BRCA1 methylation and MGMT methylation were
common in lung cancer, and occured primarily in patients without
EGFR mutations. RASSF1A methylation not only is considered one of
the pathways for the formation of lung adenocarcinoma, the
methylated BRCA1 and MGMT can also be an important step in tumor
formation and development in patients without EGFR mutations. This
theory was further strengthened by the results of analyzing the
correlation of methyl and the four genes BRCA1, MGMT, MLH1 and
RASSF1A with EGFR mutations (Table 3.15). The inversed correlation
of EGFR mutation with random methylation of an individual gene,
simultaneous 2, 3 or 4 genes found a clearer observation of genetic and
epigenetic changes in lung adenocarcinoma
27 trang |
Chia sẻ: honganh20 | Ngày: 02/03/2022 | Lượt xem: 345 | Lượt tải: 0
Bạn đang xem trước 20 trang tài liệu Tóm tắt Luận án Study on mutation, protein expression of egfr and methylation of related genes in lung adenocarcinoma patients, để xem tài liệu hoàn chỉnh bạn click vào nút DOWNLOAD ở trên
n lung
cancer
1.6.1. Methodological analysis of mutation in lung cancer
5
Gene mutations in lung cancer are detected through many
methods such as: DNA sequencing, Realtime PCR, DNA
hybridization
1.6.2. Methodological analysis of DNA methylation in lung cancer
Three common methods are used to analyze DNA
methylation including: Immune precipitation; using methyl sensitive
enzyme and based on the bisulfite treated DNA.
1.7. Study on bio markers for lung cancer in Vietnam
In order to support the lung cancer targeted treatment in
Vietnam, serveral studies have been performed to determine the
EGFR mutation in NSCLC. For example, Vu A.H. et al., Nguyen M.
H. et al., Mai T. K. et al. studied on 332, 120 and 511 patients with
NSCLC and found that the EGFR mutation rate was 40.7, 35.7 and
40.1%, respectively. Furthermore, there were serveral thesises
focusing on EGFR mutation lung cancer. However, there is no
simultaneous evaluation of EGFR molecular changes including
genetic mutations, DNA methylation, and protein overexpression
along with methylation status of tumor suppressor genes such as
MGMT, MLH1, BRCA1, RASSF1A has been published. This can be
considered a new field of research for lung cancer in Vietnam.
CHAPTER 2. MATERIALS AND METHODS
2.1. Materials
139 samples of lung tumor, 5 adjacent lung cancer samples,
healthy human blood samples were provided by Hospital K. The use of
patient samples was approved by the ethicial committee of Hospital K.
The chemicals and kits used in the study were qualified for
molecular biology analysis materials.
6
2.2. Equipments
Specialized equipments for molecular biology analysis.
2.3. Methods
This thesis research was performed at the key gene technology
laboratory, Institute of Biotechnology and Molecular Biology
laboratory, Pathology – Molecular Biology Center, Vietnam National
Cancer Hospital. It has been carried out by cross-sectional description
method, using techniques including: Total DNA extraction,
determination of DNA concentration; total DNA bisulfite treatment;
PCR; MS-PCR; electrophoresis; identify EGFR mutations;
CHAPTER 3. RESULTS
3.1. Patient characteristics
In total of 139 patients in this study, the medium age of the
patient group was 57.4. Of which 94 patients are male and 45 patients
are female. There are 79 smoking patients, of which 76/79 cases were
male. Patients in the study was belong to three main histopathological
subtypes: Acinar adenocarcinoma (56.8%), Papillary adenocarcinoma
(15.8%) and Solid adenocarcinoma (24.5%). 104 samples were
collected from primary tumors and 35 samples from metastasis tumors.
Most patients were in stage II&IV (127/139) and there were only 12
cases in stage I&II.
3.2. EGFR molecular characteristics in lung adenocarcinomas
3.2.1. EGFR mutation and correlation with patient characteristics
EGFR mutation was detected in 35.3% (49/139) patients, with
12 different types. The deletion mutation at exon 19 and the
substitution mutation at exon 21 (L858R) accounted for 85.5%. In
addition, there were six cases carried two mutations simultaneously.
7
The substitution mutation G719X usually occured concurrently with
other mutations (4/5 cases) such as S768I, L861Q, L858R and 19
deletions. EGFR mutation was higher in younger patients, women and
non - smokers. At the same time, patients with solid lung
adenocarcinoma had a lower rate of mutation compared to the other
subtypes (Table 3.3).
Table 3.3. EGFR mutation and the correlation with clinicopathologic
parameters
EGFR mutation
p
Mutation Wildtype
N 139 49 90
Age (57.4 ±10.8)
0.023
≤57.4 67 30 37
>57.4 72 19 53
Gender
<0.001
Male 94 23 71
Female 45 26 19
Smoking status
0.005
Smoker 79 20 59
Non-smoker 60 29 31
Histological subtypes
Acinar 79 32 47 0.155
Papillary 22 7 15 0.811
Micropapillary 3 2 1 0.284
Solid 34 7 27 0.042
Mixed 1 1 0 0.353
Tumors
0.787
Primary 104 36 68
Metastasis 35 13 22
Stages
0.263
I & II 12 6 6
III & IV 127 43 84
8
3.2.3. EGFR expression and correlation with patient characteristics
EGFR protein expression was assessed by
immunohistochemistry. The results showed that 57 (41.0%) samples
were negative (IHC: 0, 1+) and 82 (59.0%) samples were positive
(IHC: 2+, 3+) with EGFR expression. There was no correlation
between EGFR expression and patient characteristics including age,
gender, smoking status, histologic subtype, metastasis status, or
pathologic stage (p>0.05) (Table 3.6).
Table 3.6. EGFR expression and correlation with
clinicopathologic parameters
EGFR overexpression
p
Negative Negative
N 139 57 82
Age (57.4 ±10.8)
0.599
≤57.4 67 29 38
>57.4 72 28 44
Gender
0.191
Male 94 35 59
Female 45 22 23
Smoking status
0.627
Smoker 79 31 48
Non-smoker 60 26 34
Histological subtypes
Acinar 79 27 52 0.060
Papillary 22 9 13 0.992
Micropapillary 3 2 1 0.361
Solid 34 18 16 0.104
Mixed 1 1 0 0.229
Tumors
0.203
Primary 104 39 64
Metastasis 35 18 18
Stages
0.572
I & II 12 4 8
III & IV 127 32 95
9
3.3. Methylation of some genes involved in lung adenocarcinoma
3.3.1. Methylation of EGFR and correlation with patient
characteristics
Aberrant promoter methylation of EGFR was detected in 33
(23.7%) of a total of 139 lung adenocarcinomas. No significant
association between EGFR methylation and clinicopathologic variables
was observed.
3.3.2. Methylation of BRCA1 and correlation with patient
characteristics
Aberrant promoter methylation of BRCA1 was determined in
41 (29.5%) of a total of 139 lung adenocarcinomas. No significant
association between BRCA1 methylation and patient characteristics
was indicated.
3.3.3. Methylation of MGMT and correlation with patient
characteristics
Aberrant promoter methylation of MGMT was detected in 46
(33.1%) tumors of a total of 139 lung adenocarcinomas. Furthermore,
aberrant MGMT methylations was associated with metastasis status
(p<0.05), but not with other clinicopathologic features.
3.3.4. Methylation of MLH1 and correlation with patient
characteristics
Our results showed that aberrant promoter methylation of
MLH1 was detected in 28/139 (20.1%) of a total of 139 lung
adenocarcinomas. No significant association between MLH1
methylation and patient characteristics was observed.
3.3.5. Methylation of RASSF1A and correlation with patient
characteristics
10
Aberrant promoter methylation of RASSF1A was detected in
41 (29.5%) tumors of a total of 139 lung adenocarcinomas. The
statistically significant association between RASSF1A methylation and
smoking status was observed. Prevalence of methylation in smokers
was higher than that in non-smokers (p<0.05). Furthermore, aberrant
RASSF1A methylation were also associated with metastasis status
(p<0.05) (Table 3.11).
Table 3.11. Methylation of RASSF1A and correlation with patient
characteristics
Methyl RASSF1A
p
M U
N 139 41 98
Age (57.4 ±10.8)
≤57.4 67 20 47 0.930
>57.4 72 21 51
Gender
Male 94 29 65 0.613
Female 45 12 33
Smoking status
Smoker 79 29 50 0.032
Non-smoker 60 12 48
Histological subtypes
Acinar 79 22 57 0.625
Papillary 22 7 15 0.795
Micropapillary 3 1 2 0.883
Solid 34 11 23 0.674
Mixed 1 0 1 0.521
Tumors
Primary 104 26 78 0.045
Metastasis 35 15 20
Stages
I & II 12 4 8 0.760
III & IV 127 37 90
3.4. Correlation between mutation and expression of EGFR with
methylation of related genes in lung adenocarcinoma
11
3.4.1. Correlation between mutation, protein expression and DNA
methylation of EGFR
The mutation status exhibited no significant association with
promoter methylation and protein overexpression of EGFR (p>0.05)
but statistically correlated between EGFR methylation status and its
protein expression was observed (p<0.05) (Table 3.12).
Table 3.12. Correlation between mutation, protein expression and DNA
methylation of EGFR
EGFR methylaion EGFR mutaion
M U p + - p
33 106
49 90
EGFR expression
- 21 36 0.002 20 37 0.973
+ 12 70
29 53
EGFR mutation
+ 15 34 0.160
- 18 72
3.4.2. Correlation between mutation and expression of EGFR with
methylation of BRCA1, MGMT, MLH1 and RASSF1A
The distribution of EGFR mutations and BRCA1, MGMT, or
RASSF1A methylation were significantly exclusive in lung
adenocarcinomas. Furthermore, EGFR mutation inversely correlated
with the methylation of at least one of the four genes, at least two of
four genes or three genes (Table 15).
On other hand, EGFR expression did not correlate with
MGMT, MLH1, or RASSF1A methylation. However, BRCA1
methylation was indicated to correlate with EGFR expression
3.4.3. Correlation of methylation between genes related to lung
adenocarcinoma
In more detail, we analyzed the relationship between
methylation of each set of two out of five genes. The results showed
12
that RASSF1A methylation was correlated with BRCA1 and MLH1
(Table 17).
Table 3.15. Correlation of EGFR mutation and BRCA1, MGMT, MLH1, and
RASSF1A methylation
EGFR Mutation
N Mutation Wildtype p
Methylation 139 49 90
BRCA1 M 41 9 32 0.034
U 98 40 58
MGMT M 46 11 35 0.049
U 93 38 55
MLH1 M 28 8 20 0.408
U 111 41 70
RASSF1A M 41 7 34 0.004
U 98 42 56
1 in 4 M 90 26 64 0.041
U 49 23 26
2 in 4 M 41 6 35 0.001
U 98 43 55
3 in 4 M 17 1 16 0.004
U 122 48 74
4 in 4 M 5 0 5 0.106
U 134 49 85
CHAPTER 4. DISCUSSION
4.1. EGFR molecular characteristics in patients with lung
adenocarcinoma
4.1.1. EGFR mutation at Tyrosine Kinase Domain region
Analysis of 139 patients, we found that 35.3% of samples
occurred EGFR mutations, It is similar to previous reports in some
13
Asian countries such as Japan 32%, South Korea 36.4%; lower than
some other countries in the region such as Thailand, 57.4%, Taiwan is
55% and higher than the America and Europe (10 - 15%). EGFR
mutation occurs with high frequency in patients with lung
adenocarcinoma at National Cancer Hospital and more often in young
people, women and non-smokers. The solid adenocarcinoma has a
lower rate of mutation than other adenocarcinoma types (Table 3.3).
Midha A. et al. (2015) Summarized and analyzed 139 studies of EGFR
mutations around the world and indicated that although there are
differences in mutation rates among groups of people, geographic
regions, the rate of EGFR mutations is always higher than in women
and non-smoker patients.
Table 3.17. Correlation of tumor suppressor genes methylation
EGFR MLH1 RASSF1A MGMT
M U p M U p M U p M U p
BRCA1
M 11 30 0.580 10 31 0.419 21 20 0.001 15 26 0.571
U 22 76
18 80 20 78
31 67
MGMT
M 13 33 0.378 13 33 0.093 17 29 0.175
U 20 73
15 78 24 69
RASSF1
M 10 31 0.907 17 24 0.001
U 23 75
11 87
MLH1 M 10 18 0.096
U 23 88
4.1.2. Overexpression of EGFR protein
Evaluation of EGFR expression shows that 59.0% (82/139) of
tumor samples were positive. EGFR expression in this study is in the
same level with those reported from previous studies by Cappuzzo F.
et al. (2005) and Hirsch F.R. et al. (2008). Furthermore, we found that
EGFR expression did not correlate with clinicopathologic variables
14
(Table 3.6); which was also observed in the study of Cappuzzo F. et al.
(2005) and Liang Z. (2010). In addition, we found that overexpression
of EGFR (3+) in men was higher than in women. However, the
mechanism of this phenomenon has not been clarified. Moreover, the
level of EGFR expression in metastatic tumors tended to increase
compared to those in primary tumors. Thus, it can be assumed that the
higher degree of malignancy in metastasis tumors is the result of EGFR
overexpression.
4.1.3. Methylation of EGFR promoter region
The frequency of methylated EGFR in this study was 23.7%,
that was lower than that of Li J. et al. (2015) (36.8%) and Pan Z.Y. et
al. (2015) (35.7%). We did not find a correlation between EGFR
methylation with patient characteristics such as age, gender, smoking
status, histological subtypes, stage of disease and tumor status; The
similar results were also indicated the previous publications. However,
Li J. et al. (2015) found that patients in stage III have lower levels of
methylated EGFR than stages I and II.
4.1.4. Correlation between EGFR molecular characteristics
EGFR mutations lead to changes in amino acid sequence as
well as protein activity thereby affecting cell growth and development.
However, the level of protein expression is controlled by many
pathways in the cell including promoter methylation. Therefore,
studying the correlation of mutations, methylation and protein
expression will contribute to elucidating the mechanism of cancer
formation and development.
Studied on the correlation between gene mutation and
methylation as well as EGFR expression showed very different results.
Analysis of 139 patients, we found that there is no correlation between
15
mutation with methylation and EGFR protein expression. However,
there was a significant association between EGFR promoter
methylation and EGFR protein expression (Table 3.12). Cappuzzo F. et
al. (2005) did not find the correlation between EGFR expression and
EGFR mutation; In contrast, Liang Z. (2010) found a high level of
EGFR expression in patients with EGFR mutations. The correlation of
mutation, methylation and expression EGFR may be different between
the research groups due to differences in ethicity, age, gender and stage
of disease. Protein expression levels can be used in responding
evaluation as well as prognosis in cancer treatment. Li et al. (2013)
showed an increase in EGFR expression and programmed death in
methylated EGFR cell lines cultured in media added 5-aza-CdR and
TKIs. Therefore, regulation EGFR expression levels by methylated
DNA which combines with TKIs targeted therapy could be a new
direction not only in research but also in the treatment of lung cancer.
4.2. Methylation of tumor suppressor genes BRCA1, MGMT,
MLH1 and RASSF1A in patients with lung adenocarcinoma
4.2.1. Aberrant promoter methylations of BRCA1
Methylated BRCA1 was commonly studied in breast cancer but
had little attention in lung cancer. The hypermethylation of BRCA1 can
be considered a tumorigenesis pathway in addition to the EGFR or
KRAS mutation. The rate of BRCA1 methylation in various studies
ranges from 4 - 54%. The frequency of methylated BRCA1 in this
study was 29.5% which was higher than in American patients (4%) and
lower than in Chinese (30 - 54%). This results could be explained by
the differences in ethicity and geography of patient populations. In
Asian populations, BRCA1 methylation tends to occur more commonly
than Western patients.
16
In this study, there was no correlation between methyl BRCA1
and patient characteristics. In previous studies, they were not although
fully studying the features, but most of them showed no correlation
between clinicopathologic variables and methylation BRCA1. Gao W.
et al. (2016) indicated that BRCA1 methylation tended to increase in
stage II and III than stage I; in patients with lymph node metastasis
compared with patients without lymph node metastasis. From these
results can be assumed that methylated BRCA1 occurs in parallel with
the progression of the disease, the more the disease progresses the
greater the level of methylation. In this study, we also found an
increase in the methylation status of BRCA1 with disease progression
but it is not significant. Therefore, methylation of BRCA1 can be
considered as one of the causes leading to the tumorigenesis and
development of lung adenocarcinoma and needs to be studied in detail.
4.2.2. Aberrant promoter methylations of MGMT
MGM methylation has been observed in many cancers
including lung cancer. The percentage of MGMT methylation was in
various studies from 8 to 50%. The frequency of methylated MGMT in
this study was 33.1%; It was higher than the reports of Feng Q. et al.
(2008) (8%), Kim et al. (2005) (17%); and similar to other researches
which were performed on Chinese patients (30-50%). MGMT
methylation inhibits protein expression and reduces the MGMT DNA
repair function leading to increase the mutation establishment. The
results of correlation analysis showed that MGMT methylation is not
associated with the patient characteristics in the study excepted
metastasis status. Reports on Korean and Chinese patients have
showed similar results. In this study, we found an increase in the
MGMT methylation in metastatic tumors. Although the mechanism for
17
promoting methylated MGMT in metastatic cells in lung cancer has not
been elucidated, it can be seen that MGMT methylation may contribute
to accelerating tumor metastases and disease progression. MGMT
methylation could be considered as one of the standard markers
supporting the prognosis and treatment of lung cancer.
4.2.3. Aberrant promoter methylations of MLH1
Study on MLH1 methylation is popular in lung cancer, but the
rate of methylation varies widely among the studies. The previously
published MLH1methylation frequency ranges from 0 to 58%. The
ratio of methylataed MLH1 in our research was 20.1% which is higher
than a report of Tang M. et al. (2006) (0%); and lower than publishes
in Asian patients (30-50%). In addition, Seng T.J. et al. (2008)
compared survival rates of methylated and unmethylated MLH1
patients, and suggested that patients with the MLH1 methylation had a
poor prognosis and lower survival time than the unmethylated group.
MLH1 methylation could be one of the standard markers in the
prognostic assessment for lung cancer patients along with other
markers.
MLH1 methylation studies on different patient groups have
been performed and showed no correlation between MLH1 methylation
with patient features such as age, gender, smoking status. The reports
often did not go into the different subtypes of adenocarcinoma, but
only focus on patients with adenocarcinoma. However, the status of
methylated MLH1 at different stages of the disease showed
inconsistencies between the studies. In the publication of Seng T.J. et
al. (2008), the author found that the rate of methylation MLH1 in
patients with stage II was higher than in stage I (40/86 compared to
46/153). In contrast, Wang Y.C. et al. (2003) indicated that the
18
difference in MLH1 methylation level in the group of patients with
advanced stage and early stage patients (stage III and IV compared
with stages I and II) was not statistically significant. In this study, we
also did not observe differences in the level of methylation MLH1 at
different stages of the disease (patients in the study were
predominantly in late stages) as well as at the tumor status (primary or
metastatic tumors). With the function of DNA mismatches repair in
replication process, it is possible to hypothesize that the MLH1
methylation occurs mainly during the invasive stage of the tumor when
cancer progress from stage I to stage II. In this process, the DNA
mismatch repair function of the cell is impaired and the secondary
mutations are generated before entering the metastatic stage.
4.2.4. Aberrant promoter methylations of RASSF1A
RASSF1A is involved in regulating many important processes
in the cell including the cell cycle as well as the programmed death
process. Methylation of RASSF1A is crucial to inhibiting expression of
this protein. Therefore, RASSF1A methylation has become a standard
marker in the diagnosis and treatment of lung cancer. The rate of
methylated RASSF1A in the previous studies varies from 20 to 80%.
The frequency of RASSF1A methylation in our study was 29.5% (Table
2.17). As reported by de Fraipont F. et al. (2012) on overall survival
and progression-free survival of two groups of patients after
chemotherapy. The results showed that the methylated RASSF1A group
had shorter survival time than the unmethylated group (progression-
free survival 16.7 versus 61.2 months and overall survival 32.9
compared to 84 months). It can be seen that determination of RASSF1A
methylation status should be considered as one of the prognostic
factors for lung cancer patients.
19
Methylation of RASSF1A has been associated to smoking
habit, and the correlation between RASSF1A methylation and smoking
status of patients has also been published in several studies, such as
Yanagawa N. et al. (2011) and Lee S.M. et al. (2011). Therefore,
smoking can be the cause of methylated RASSF1A in patients with lung
cancer. Besides the EGFR mutation, methylation of RASSF1A may be
an important mechanism in the carcinogenesis and development of
lung cancer. Previously, RASSF1A has also been showed to inhibit the
invasion and metastasis of lung cancer cell lines by prohibiting YAP
(Yes-associated protein) protein. In our study, the level of RASSF1A
methylation in metastatic tumors was higher than in primary tumors.
The results proved that methylation of RASSF1A is not only involved
in tumorigenesis but also plays an important role in tumor metastasis in
lung cancer. Therefore, the identification of RASSF1A methylation
status is becoming increasingly necessary for patients, contributing to
the diagnosis as well as prognosis.
4.3. Correlation of EGFR alterations with aberrant promoter
methylations of BRCA1, MGMT, MLH1, and RASSF1A in lung
adenocarcinoma
4.3.1. Correlation of EGFR mutation with methylation of tumor
suppressor genes
Gene mutations and DNA methylation are the two main
pathways for cancer generation and development. The interaction of
these two pathways has been found in many types of cancer. In this
study, we analyzed the interaction between EGFR mutation and
methylation of four tumor suppressor genes typical of lung
adenocarcinoma. Results showed that EGFR mutation and methylation
of tumor suppressor genes tended to occur in opposite directions and
20
mutually exclusive (Table 3.1). The inversed correlation between
EGFR mutation and RASSF1A methylation has been mentioned in a
number of previous studies. Yanagawa N. et al. (2011) and Hoque
M.O. et al. (2010) showed an inversed association simultaneously
between RASSF1A methylation with smoking status and EGFR
mutation. This study has confirmed the mutual exclusion of these two
phenomena. At the same time, with the above analysis, EGFR mutation
occurs in non-smokers, whereas methylation of RASSF1A is common
in smokers. Therefore, it can be hypothesized that in non-smokers,
adenocarcinoma lung cancer may be established by EGFR mutation. In
contrast, lung adenocarcinoma in smokers are formed via the
methylation of RASSF1A.
In addition, in the study, we also showed the inversed
correlation between EGFR mutation and methylation BRCA1 and
MGMT (Table 3.15). The study of methylation of BRCA1 and MGMT
has received limited attention in lung cancer. However, our results
showed that BRCA1 methylation and MGMT methylation were
common in lung cancer, and occured primarily in patients without
EGFR mutations. RASSF1A methylation not only is considered one of
the pathways for the formation of lung adenocarcinoma, the
methylated BRCA1 and MGMT can also be an important step in tumor
formation and development in patients without EGFR mutations. This
theory was further strengthened by the results of analyzing the
correlation of methyl and the four genes BRCA1, MGMT, MLH1 and
RASSF1A with EGFR mutations (Table 3.15). The inversed correlation
of EGFR mutation with random methylation of an individual gene,
simultaneous 2, 3 or 4 genes found a clearer observation of genetic and
epigenetic changes in lung adenocarcinoma. Our results have also
21
showed that gene mutation and DNA methylation of tumor suppressor
genes are two pathways leading to the formation and development of
lung cancer. Therefore, it can be considered that DNA methylation
needs to be researched and tested as a target for cancer treatment.
4.3.2. Correlation of EGFR expression with methylation of tumor
suppressor genes
In this study, we found that EGFR expression increased in
patients without methylated BRCA1. Although the mechanism of
correlation between BRCA1 methylation and EGFR protein expression
has not been clarified, it can be seen that methylaed BRCA1 is involved
in inhibiting EGFR expression. However, there were a few studies on
lung cancer have been conducted to clarify the mechanism of
Các file đính kèm theo tài liệu này:
- tom_tat_luan_an_study_on_mutation_protein_expression_of_egfr.pdf